Larotaxel with cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: A randomized, active-controlled, phase III trial (CILAB)

Oncology (Switzerland)

Volumn 85, Issue 4, 2013, Pages 208-215

  Sternberg, Cora N ^a   Skoneczna, Iwona A ^b   Castellano, Daniel ^c   Theodore, Christine ^e   Blais, Normand ^h   Voog, Eric ^f   Bellmunt, Joaquim ^d   Peters, Frank ⁱ   Le Guennec, Solenn ^g   Cerbone, Linda ^a   Risse, Marie Laure ^g   MacHiels, Jean Pascal ^j  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e FOCH HOSPITAL   (France)

^f CENTRE JEAN BERNARD   (France)

^g SANOFI   (France)

^h NOTRE DAME HOSPITAL   (Canada)

ⁱ Zuyderland Medical Centre   (Netherlands)

^j UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

more..

Author keywords

Cisplatin; Larotaxel; Survival; Taxoids; Urologic neoplasms; XRP9881

Indexed keywords

CISPLATIN; CREATININE; GEMCITABINE; LAROTAXEL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BACKACHE; BLADDER CANCER; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSGEUSIA; DYSPEPSIA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HEMATURIA; HICCUP; HUMAN; HYPERSENSITIVITY; INSOMNIA; KIDNEY CLEARANCE; LEUKOPENIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; URINARY TRACT INFECTION; WEIGHT REDUCTION;

EID: 84888219788     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000354085     Document Type: Article

References (21)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of the worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985; 133: 403-407.
3. Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, Weiselberg L, Rosado K, Smart T, Lin SY, Penenberg D, Fair WR, Whitmore WF: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989; 64: 2448-2458.
4. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068-3077.
5. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-4608.
6. Pectasides D, Pectasides M, Economopoulos T: Systemic chemotherapy in locally advanced and/or metastatic bladder cancer. Cancer Treat Rev 2006; 32: 456-470.
7. Siefker-Radtke A: Systemic chemotherapy options for metastatic bladder cancer. Expert Rev Anticancer Ther 2006; 6: 877-885.
8. National Comprehensive Cancer Network guidelines 2012: bladder cancer. http://www. nccn.org/professionals/physician-gls/pdf/bladder.pdf (accessed December 12, 2012).
9. Shelley M, Cleves A, Wilt TJ, Mason M: Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. Cochrane Database Syst Rev 2011, p CD008976.
10. Dimopoulos MA, Bakoyannis C, Georgoulias V, Papadimitriou C, Moulopoulos LA, Deliveliotis C, Karayannis A, Varkarakis I, Aravantinos G, Zervas A, Pantazopoulos D, Fountzilas G, Bamias A, Kyriakakis Z, Anagnostopoulos A, Giannopoulos A, Kosmidis P: Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 1999; 10: 1385-1388.
11. Garcia del Muro X, Marcuello E, Gumá J, Paz-Ares L, Climent MA, Carles J, Parra MS, Tisaire JL, Maroto P, Germá JR: Phase II multicenter study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 2002; 86: 326-330.
12. Sengelov L, Kamby C, Lund B, Engelholm SA: Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 1998; 16:3392-3397.
13. Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G: Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group study. J Clin Oncol 2000; 18: 1058-1061.
14. Burch PA, Richardson RL, Cha SS, Sargent DJ, Pitot HC 4th, Kaur JS, Camoriano JK: Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol 2000; 164: 1538-1542.
15. Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias C, Kosmidis P, Dimopoulos MA; Hellenic Cooperative Oncology Group: Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 2004; 22: 220-228.
16. Sessa C, Cuvier C, Caldiera S, Bauer J, Van Den Bosch S, Monnerat C, Semiond D, Pérard D, Lebecq A, Besenval M, Marty M: Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann Oncol 2002; 13: 1140-1150.
17. Metzger-Filho O, Moulin C, de Azambuja E, Ahmad A: Larotaxel: broadening the road with new taxanes. Expert Opin Investig Drugs 2009; 18: 1183-1189.
18. Diéras V, Limentani S, Romieu G, Tubiana-Hulin M, Lortholary A, Kaufman P, Girre V, Besenval M, Valero V: Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol 2008; 19: 1255-1260.
19. Zatloukal P, Gervais R, Vansteenkiste J, Bosquee L, Sessa C, Brain E, Dansin E, Urban T, Dohollou N, Besenval M, Quoix E: Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV nonsmall cell lung cancer. J Thorac Oncol 2008; 3: 894-901.
20. Vrignaud P, Lejeune P, Bissery MC: In vivo synergy between doxorubicin, cisplatin or vinorelbine and RPR 109881A, a new taxoid (abstract 3414). Proc Am Assoc Cancer Res 2005; 46.
21. Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR, Winquist E, Raghavan D, Marreaud S, Collette S, Sylvester R, de Wit R: Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012; 30: 1107-1113.